bioimagesUnknownKasper FuggerThe Journal of Cell Biologyhttps://www.ebi.ac.uk/biostudies/studies/S-JCBD-200812138JCB

U2OS/GFP-hFbh1 WT cells were left untreated for 24 h, and subjected to IR for 1 h. The cells were then pre-extracted to remove soluble proteins, fixed and co-immunostained with RPA and Rad51 antibodies.

U2OS/NLS-GFP-hFbh1 WT cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, pre-extracted, fixed and co-immunostained with RPA (red) and Rad51 (blue).

EMSA with hFbh1, using 32P-labelled ssDNA or dsDNA probes, which were incubated with increasing amounts (200-1000 nM) of GST-hFbh1 and subjected to native gel electrophoresis. The resulting GST-hFbh1/probe complex is seen as a slower migrating band.

U2OS/GFP-hFbh1 WT cells were induced with DOX for 24 h, and subjected to HU for 2 h. The cells were then pre-extracted to remove soluble proteins, fixed and co-immunostained with RPA and Rad51 antibodies.

U2OS cells expressing GFP-hFbh1 were transfected with indicated siRNAs for 24 h. One day later, cells were induced with DOX for an additional 24 h, and subsequently exposed to HU for 1 h.

U2OS/NLS-GFP-hFbh1 *HL cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, fixed and co-immunostained with BrdU (red) and Cyclin A (blue).

IR-treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and γ-H2AX (violet).

U2OS cells expressing GFP-hFbh1 were labelled with BrdU for 24 h, and subsequently treated with HU for 1h. Cells were fixed and stained for BrdU (red).

Mock treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and γ-H2AX (violet).

U2OS/NLS-GFP-hFbh1 WT cell line was uninduced in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, pre-extracted, fixed and co-immunostained with RPA (red) and Rad51 (blue).

U2OS cells expressing GFP-hFbh1 were treated with HU, and collected at the indicated time points. Cells were fixed and co-immunostained for RPA (red).

U2OS cells expressing GFP-hFbh1 were transfected with indicated siRNAs for 24 h. One day later, cells were induced with DOX for an additional 24 h, and subsequently exposed to IR and collected after 1 h.

U2OS/NLS-GFP-hFbh1 WT cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, fixed and co-immunostained with BrdU (red) and Cyclin A (blue).

HU-treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and γ-H2AX (violet).

U2OS/GFP-hFbh1 WT cells were induced with DOX for 24 h, and subjected to IR for 1 h. The cells were then pre-extracted to remove soluble proteins, fixed and co-immunostained with RPA and Rad51 antibodies.

IR-treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were labelled with BrdU for 30 minutes, fixed and co-immunostained with antibodies to BrdU (red) and Cyclin A (blue).

U2OS/GFP-hFbh1 cells were induced with DOX for 24 h, and irradiated with UV-C (100 J/m2) through a polycarbonate filter with 5 μm pores. Thirty min later, cells were fixed and immunostained with Cyclin A antibody.

U2OS/GFP-hFbh1 WT cells were left untreated for 24 h, and subjected to HU for 2 h. The cells were then pre-extracted to remove soluble proteins, fixed and co-immunostained with RPA and Rad51 antibodies.

U2OS/sh-hFbh1 cells were induced with Dox for 48 h, and incubated in the presence of BrdU for an additional 24 h. Cells were then treated with HU for 2 h, and processed for native fixation and immunostaining with BrdU antibody and DAPI.

U2OS/sh-hFbh1 cells were left untreated for 48 h, and incubated in the presence of BrdU for an additional 24 h. Cells were then treated with HU for 2 h, and processed for native fixation and immunostaining with BrdU antibody and DAPI.

U2OS/NLS-GFP-hFbh1 WT cell line was uninduced in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, fixed and co-immunostained with BrdU (red) and Cyclin A (blue).

IR-treated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and Cyclin A (magenta).

BJ cells were transfected with control or hFbh1 siRNAs for 48 h and subjected to sister chromatid exchange (SCE) analysis. Image shows a representative metaphase chromosome spread from hFbh1-depleted cells.

U2OS/NLS-GFP-hFbh1 *HL cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, pre-extracted, fixed and co-immunostained with RPA (red) and Rad51 (blue).

U2OS cells expressing GFP-hFbh1 were transfected with indicated siRNAs for 24 h. One day later, cells were induced with DOX for an additional 24 h, and subsequently exposed to IR for 1 h.

Micro-irradiated U2OS cells expressing GFP-hFbh1. One hour after treatment, cells were fixed and co-immunostained with antibodies to RPA (red) and γ-H2AX (violet).

U2OS/NLS-GFP-hFbh1 *FB cell line was induced with DOX in the presence of BrdU for 24 h. Cells were treated with HU for 1 h, fixed and co-immunostained with BrdU (red) and Cyclin A (blue).

bioimagesImage 782 (Figure 4 - B)Image 763 (Figure 1 - C)Image 755 (Figure 1 - A)Image 3797 (Figure 4 - D)Image 769 (Figure 2 - A)Image 3793 (Figure 3 - A)Image 759 (Figure 1 - C)Image 778 (Figure 4 - B)Image 771 (Figure 2 - B)Image 761 (Figure 1 - C)Image 3791 (Figure 2 - D)Figure 1 - AImage 760 (Figure 1 - C)Image 753 (Figure 1 - A)Figure 1 - CFigure 1 - BImage 3800 (Figure 2 - A)Figure 2 - CFigure 2 - DFigure 2 - AFigure 2 - BImage 779 (Figure 4 - B)Image 757 (Figure 1 - B)Image 3788 (Figure 2 - A)Image 765 (Figure 2 - A)Image 764 (Figure 1 - C)Figure 3 - AImage 3794 (Figure 3 - A)Figure 4 - BImage 762 (Figure 1 - C)Image 781 (Figure 4 - B)Image 768 (Figure 2 - A)Image 777 (Figure 4 - B)Image 3798 (Figure 4 - D)Image 754 (Figure 1 - A)Figure 4 - DImage 767 (Figure 2 - A)Figure 5 - AImage 770 (Figure 2 - A)Image 776 (Figure 4 - B)Image 784 (Figure 5 - A)Image 3795 (Figure 3 - A)Image 775 (Figure 4 - B)Figure 5Image 756 (Figure 1 - A)Figure 4Image 766 (Figure 2 - A)Image 774 (Figure 2 - C)Image 758 (Figure 1 - B)Image 3796 (Figure 3 - A)Image 780 (Figure 4 - B)Figure 1Figure 3Figure 2Jannie Rendtlew DanielsenJiri BartekNiels MailandJacob FalckJiri LukasKasper FuggerChristoffel DinantMartin MistrikfalseHuman Fbh1 helicase contributes to genome maintenance via pro- and anti-recombinase activities2009-09-07T11:17:21Z2018-11-29T11:17:21Z2018-11-29T11:17:21ZS-JCBD-20081213810.1083/jcb.200812138